Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.52)
# 853
Out of 5,127 analysts
68
Total ratings
59.57%
Success rate
18.46%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $102.82 | +2.12% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $15.86 | +26.10% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $80.10 | -5.12% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $11.23 | +24.67% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $117.25 | -14.71% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $22.31 | +38.95% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $18.54 | -51.46% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $47.47 | -30.48% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $143.58 | +32.33% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $29.36 | -35.29% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $328.14 | +18.85% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $57.12 | -3.71% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $105.34 | -47.79% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $127.50 | +25.49% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $546.76 | +22.54% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.07 | +294.48% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,380.88 | +1.38% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.84 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $42.10 | +113.78% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $216.66 | +24.62% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $102.82
Upside: +2.12%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $15.86
Upside: +26.10%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $80.10
Upside: -5.12%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $11.23
Upside: +24.67%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $117.25
Upside: -14.71%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $22.31
Upside: +38.95%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $18.54
Upside: -51.46%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $47.47
Upside: -30.48%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $143.58
Upside: +32.33%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $29.36
Upside: -35.29%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $328.14
Upside: +18.85%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $57.12
Upside: -3.71%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $105.34
Upside: -47.79%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $127.50
Upside: +25.49%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $546.76
Upside: +22.54%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.07
Upside: +294.48%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,380.88
Upside: +1.38%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.84
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $42.10
Upside: +113.78%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $216.66
Upside: +24.62%